Eli Lilly's combo therapy for COVID-19 cuts serious illness and death in large study
(Reuters) - Eli Lilly and Co said on Wednesday that its combination antibody therapy to fight COVID-19 reduced the risk of hospitalization and death by 87% in a study of more than 750 high-risk COVID-19 patients.
It is the second large, late-stage study to show that combination therapy of two antibodies, bamlanivimab and etesevimab, is effective at treating mild to moderate cases of COVID-19. The previous study, which published data in January, used a higher dose of the drugs and reduced risk of hospitalization by 70%.
“I expect this data to continue to drive more utilization” of the antibodies,” said Daniel Skovronsky, chief scientific officer at Eli Lilly. “We have few other diseases where we have drugs that can offer this magnitude of benefit.”
snip
Skovronsky said that Lilly is prepared to manufacture 1 million doses of the combination therapy in the coming months and is in active talks to supply governments around the world with the treatment.
(Read More) https://www.reuters.com/article/us-health-coronavirus-lilly/eli-lillys-combo-therapy-for-covid-19-cuts-serious-illness-and-death-in-large-study-idUSKBN2B21C0
